[1]臧涵怡,包欣,赵伟.雷珠单抗1+PRN和3+PRN治疗湿性年龄相关性黄斑变性的对比研究[J].眼科新进展,2021,41(11):1072-1076.[doi:10.13389/j.cnki.rao.2021.0225]
　ZANG Hanyi,BAO Xin,ZHAO Wei.Efficacy of ranibizumab 1+PRN and 3+PRN in the treatment of wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(11):1072-1076.[doi:10.13389/j.cnki.rao.2021.0225]
点击复制

雷珠单抗1+PRN和3+PRN治疗湿性年龄相关性黄斑变性的对比研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年11期
页码:
1072-1076
栏目:
应用研究
出版日期:
2021-11-05

文章信息/Info

Title:
Efficacy of ranibizumab 1+PRN and 3+PRN in the treatment of wet age-related macular degeneration
作者:
臧涵怡; 包欣; 赵伟
214023　江苏省无锡市，无锡市人民医院眼科
Author(s):
ZANG Hanyi; BAO Xin; ZHAO Wei
Department of Ophthalmology,Wuxi People’s Hospital,Wuxi 214023,Jiangsu Province,China
关键词:
年龄相关性黄斑变性; 雷珠单抗; 视觉电生理
Keywords:
age-related macular degeneration;  ranibizumab;  visual electrophysiology
分类号:
R774
DOI:
10.13389/j.cnki.rao.2021.0225
文献标志码:
A
摘要:
目的　探讨雷珠单抗1+按需治疗方案（PRN）和3+PRN治疗湿性年龄相关性黄斑变性（AMD）的疗效和安全性。方法　前瞻性随机对照研究。选择2018年3月至2020年4月本院收治的152例（152眼）湿性AMD患者作为研究对象，采用随机数字表法将患者分为1+PRN组（77例77眼）和3+PRN组（75例75眼）。1+PRN组患者在基线治疗期（第0个月）玻璃体内注射雷珠单抗0.5 mg，在第1~12个月采用PRN；3+PRN组患者在核心治疗期（第0、1、2个月）给予玻璃体内注射0.5 mg雷珠单抗（共3次），在延长治疗期采用PRN。统计随访期间两组患者最佳矫正视力（BCVA）、中心凹视网膜厚度（CMT）、平均病灶隆起最高点视网膜厚度（HLT）、平均病灶中央视网膜厚度（CLT），进行视觉电生理检查，统计闪光视网膜电图（FERG）a波、b波潜时及波幅，记录图形视觉诱发电位（PVEP）P100波、闪光视觉诱发电位（FVEP）P100波的潜时及波幅；并统计两组患者的不良反应。结果　1+PRN组、3+PRN组患者核心治疗期内玻璃体内注药次数分别为（2.40±0.70）次、3.00次；随访12个月内注药次数分别为（6.22±2.01）次、（6.33±2.01）次，差异均无统计学意义（均为P>0.05）。与注药前相比，两组患者治疗后BCVA均显著升高（均为P<0.05），两组患者不同时间点BCVA比较，差异均无统计学意义（均为P>0.05）。两组患者治疗后CMT、HLT、CLT均显著降低（均为P<0.05），组间比较差异均无统计学意义（均为P>0.05）。两组患者治疗后FERG a波、b波及PVEP P100波的潜时均显著降低（均为P<0.05），FERG a波、b波及PVEP P100波、FVEP P100波的波幅均显著升高（均为P<0.05），两组比较差异均无统计学意义（均为P>0.05）。两组患者均未见严重全身及眼部不良反应。结论　雷珠单抗1+PRN及3+PRN治疗湿性AMD疗效相似，临床上可根据患者需求选择合适的治疗方案。
Abstract:
Objective　To investigate the efficacy and safety of ranibizumab 1 + pro re nata (PRN) and ranibizumab 3 + PRN in the treatment of wet age-related macular degeneration (AMD).Methods　In this prospective randomized controlled study, 152 patients (152 eyes) with wet AMD who were admitted to the hospital between March 2018 and April 2020 were enrolled. Through random number table method, the patients were divided into 1+PRN group (77 patients, 77 eyes) and 3+PRN group (75 patients, 75 eyes). The 1+PRN group was treated with intravitreal injection of 0.5 mg of ranibizumab at baseline (before treatment) and was then given PRN treatment in the 1st to 12th months. The 3+PRN group was treated with intravitreal injection of 0.5 mg of ranibizumab 3 times during the core treatment period (0, 1st, 2nd month) and was then given PRN treatment during the extended treatment period. The best corrected visual acuity (BCVA), central macular thickness (CMT), mean retinal thickness at the highest point of eminence lesion (HLT), and mean focal central retinal thickness(CLT) during follow-ups were recorded. Visual electrophysiological examination was performed. The latent time and amplitudes of a and b waves of flash electroretinogram (FERG), as well as P100 waves of pattern visual evoked potential (PVEP) and flash visual evoked potential (FVEP) were recorded.Adverse reactions were also recorded. Results　The numbers of injections for 1+PRN group and 3+PRN group during the core treatment period were (2.40±0.70) times and 3 times, respectively. The numbers of injections within 12 months of follow-up were (6.22±2.01) times and (6.33±2.01) times, respectively, without statistically significant difference (P>0.05). The BCVA of the two groups increased significantly after treatment (both P<0.05), but there were no significant differences in BCVA changes between the two groups at different time points (all P>0.05). After treatment, CMT, HLT, and CLT were significantly reduced (all P<0.05), without statistically significant differences between the two groups (all P>0.05). After treatment, the latent time of FERG a wave, FERG b wave, and PVEP P100 wave was significantly reduced in the two groups (all P<0.05). The amplitudes of FERG a wave, FERG b wave, PVEP P100 wave, and FVEP P100 wave were significantly increased (all P<0.05), without statistically significant differences between the two groups (all P>0.05). No serious systemic or ocular adverse reactions were observed in the two groups.Conclusion　Ranibizumab 1+PRN and ranibizumab 3+PRN have similar therapeutic effects. Patients can select any of them according to their needs.

参考文献/References:

［1］　JAFFE G J,WESTBY K,CSAKY K G,MONS J,PEARLMAN S S,JOONDEPH B C,et al.C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration：a randomized pivotal phase 2/3 trial［J］.Ophthalmology,2021,128(4):576-586.
［2］　DUGEL P U,SINGH R P,KOH A,OGURA Y，HOLZ F G.HAWK and HARRIER：96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration［J］.Ophthalmology,2021,128(1):89-99.
［3］　LEE S W,SIM H E,PARK J Y,KIM J S,CHANG I B,PARK Y S.Changes in inner retinal layer thickness in patients with exudative age-related macular degeneration during treatment with anti-vascular endothelial growth factor［J］.Medicine,2020,99(17):e19955.
［4］　TOLD R,REITER G S,MITTERMLLER T J,SCHRANZ M,REUMUEIIER A,SCHLANITZ F G,et al.Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-ascular endothelial growth factor therapy using SSOCTA［J］.Acta Ophthalmol,2021,99(2):e240-e246.
［5］　张雨晴,周琼,邵毅,葛倩敏， 杨林，石文卿，等.玻璃体内注射雷珠单抗对年龄相关性黄斑变性患者眼表的影响［J］.眼科新进展,2020,40(3):235-238.
ZHANG Y Q,ZHOU Q,SHAO Y,GE Q M,YANG L,SHI W Q,et al.The effect of intravitreal injection of ranibizumab on the ocular surface of patients with age-related macular degeneration［J］.Rec Adv Ophthalmol,2020,40(3):235-238.
［6］　闫淑,邵玲,杜敏,沈策英,李琰,刘钰,等.湿性年龄相关性黄斑变性玻璃体注射雷珠单抗治疗一年后视力的影响因素［J］.眼科,2019,28(6):433-437.
YAN S,SHAO L,DU M,SHEN C Y,LI Y,LIU Y,et al.Effective factors of one-year visual outcomes after intravitreal injection of ranibizumb for wet age-related macular degeneration［J］.Ophthalmol CHN,2019,28(6):433-437.
［7］　FINN A P,PISTILLI M,TAI V,DANIEL E,YING G S,MAGUIRE M G,et al.Localized optical coherence tomography precursors of macular atrophy and fibrotic scar in the comparison of age-related macular degeneration treatments trials［J］.Am J Ophthalmol,2021,223:338-347.
［8］　SPOONER K L,FRASER-BELL S,COZZI M,STAURENGHI G,INVERNIZZI A,MONTEDURO D,et al.Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors using a treat-and-extend or a pro-re-nata regimen：four year results of the MANEX study［J］.Ophthalmology,2020,127(12):1663-1673.
［9］　程琳,李强,王超,段俊国.ETDRS标准对数视力表视力测试［J］.中华实验眼科杂志,2011,29(6):574-575.
CHENG L,LI Q,WANG C,DUAN J G.ETDRS standard logarithmic visual acuity chart visual acuity test［J］.Chin J Exp Ophthalmol,2011,29(6):574-575.
［10］　中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会.中国老年性黄斑变性临床诊断治疗路径［J］.中华眼底病杂志,2013,29(4):343-355.
The Clinical Guideline and Clinical Pathway Development Committee for Age-Related Macular Degeneration,Ocular Fundus Diseases Society,Chinese Ophthalmological Society,Chinese Medical Associate.Clinical diagnosis and treatment path of age-related macular degeneration in China［J］.Chin J Ocul Fundus Dis,2013,29(4):343-355.
［11］　ESTEBAN O,ASCASO F J,MATEO J,CALVO T,RUIZ-PESINI E.Effects of mitochondrial haplogroups on ranibizumab response in neovascular age-related macular degeneration patients:a pilot study［J］.Acta Ophthalmol,2019,97(1):e133-e134.
［12］　MILLER J W.Comparison of age-related macular degeneration treatments trials 2：introducing comparative effectiveness research［J］.Ophthalmology,2020,127(4S):S133-S134.
［13］　WANG F,YUAN Y,WANG L,YE X,ZHAO J,SHEN M,et al.One-year outcomes of 1 dose versus 3 loading doses followed by pro re nata regimen using ranibizumab for neovascular age-related macular degeneration：the ARTIS trial［J］.J Ophthalmol,2019,2019:753048.
［14］　ELWES F,BOROOAH S,ASPINALL P,SIM PY， LOO C Y，ARMBRECHT A M,et al.Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab［J］.BMC Ophthalmol,2018,18(1):20.
［15］　顾鹏,霍姝佳,王青,孙成，刘勇.视网膜色素变性患者黄斑区微视野检测参数与视网膜结构的相关性分析［J］.第三军医大学学报,2019,41(3):247-251.
GU P,HUO S J,WANG Q,SUN C,LIU Y.Analysis of the correlation between microscopic field detection parameters and retinal structure in patients with retinitis pigmentosa［J］.J Third Milit Med Univ,2019,41(3):247-251.
［16］　李静,杨艳,任杰,梁军，谷威.影响特发性黄斑前膜术后视力的相关因素分析［J］.眼科,2019,28(4):269-272.
LI J,YANG Y,REN J,LIANG J,GU W.Analysis of related factors affecting visual acuity after operation of idiopathic macular epithelium［J］.Ophthalmology,2019,28(4):269-272.
［17］　PARRY N,MCKEEFRY D J,MURRAY I J,KREMERS J.New developments in non-invasive visual electrophysiology［J］.Vision Res,2020,174:77-78.
［18］　李世迎,王刚,魏世辉.重视视觉电生理检查和相干光层析成像术在视神经疾病中的联合应用［J］.中华眼科杂志,2019,55(3):161-163.
LI S Y,WANG G,WEI S H.Pay attention to the combined application of visual electrophysiological examination and coherent optical tomography in optic nerve diseases［J］.Chin J Ophthalmol,2019,55(3):161-163.
［19］　邓吕红,谭钢,吴恺,王水莲.康柏西普、雷珠单抗单次玻璃体注射治疗渗出型年龄相关性黄斑变性疗效比较［J］.中南医学科学杂志,2018,46(6):657-659,666.
DENY L H,TAN G,WU K,WANG S L.Effect of single vitreous injection of compaxerib and ralizumab in the treatment of exudative age-related macular degeneration［J］.J Univ South China(Med Ed),2018,46(6):657-659,666.
［19］　陈有信,汤加.抗血管内皮生长因子治疗眼部新生血管性疾病问题与挑战［J］.中华实验眼科杂志,2019,37(1):1-4.
CHEN Y X,TANG J.The problems and challenges of anti-vascular endothelial growth factor in the treatment of ocular neovascular diseases［J］.Chin J Exp Ophthalmol,2019,37(1):1-4.
［20］　GLVEZ M I L,BARQUET L A,FIGUEROA M S,GARCALAYANA A,MORENO J M R.Bimonthly,treat-and-extend and as needed ranibizumab in nave neovascular age-related macular degeneration patients：12-month outcomes of a randomized study［J］.Acta Ophthalmol,2020,98(7):e820-e829.
［21］　SHARMA A,KUMAR N,PARACHURI N,KUPPERMANN B D，BANDELLO F,REGILLO C D.Ranibizumab port delivery system（RPDS)：realising long awaited dream of prolonged VEGF suppression［J］.Eye,2020,34(3):422-423.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[5]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[6]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[7]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[8]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[9]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]胡军平,杨华,李国栋,等.光动力疗法联合玻璃体内注射雷珠单抗治疗湿性年龄相关性黄斑变性后黄斑区中心视野的改变[J].眼科新进展,2015,35(11):1039.[doi:10.13389/j.cnki.rao.2015.0284]
　HU Jun-Ping,YANG Hua,LI Guo-Dong,et al.Macular visual field changes after combined photodynamic therapy and intravitreal injection of ranibizumab for neovacular age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(11):1039.[doi:10.13389/j.cnki.rao.2015.0284]
[12]郑燕林,彭晓丽,陈廷,等.Lucentis治疗黄斑脉络膜新生血管1年的临床疗效观察[J].眼科新进展,2016,36(4):348.[doi:10.13389/j.cnki.rao.2016.0094]
　ZHENG Yan-Lin,PENG Xiao-Li,CHEN Ting,et al.Clinical effects of Lucentis in treatment of macular choroid neovascularization for l year[J].Recent Advances in Ophthalmology,2016,36(11):348.[doi:10.13389/j.cnki.rao.2016.0094]
[13]赵露,洪慧,谢国丽,等.玻璃体内注射雷珠单抗对湿性年龄相关性黄斑变性患者脉络膜厚度及睫状后动脉血流的影响[J].眼科新进展,2016,36(8):745.[doi:10.13389/j.cnki.rao.2016.0198]
　ZHANG Lu,HONG Hui,XIE Guo-Li,et al.Effects of intravitreal ranibizumab injection on subfoveal choroidal thickness and posterior ciliary artery hemodynamics in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(11):745.[doi:10.13389/j.cnki.rao.2016.0198]
[14]刘志南,管怀进.雷珠单抗和阿柏西普对年龄相关性黄斑变性患者外层视网膜管状结构的影响[J].眼科新进展,2019,39(10):952.[doi:10.13389/j.cnki.rao.2019.0217]
　LIU Zhi-Nan,GUAN Huai-Jin.Effects of ranibizumab and aflibercept on outer retinal tubulation of patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2019,39(11):952.[doi:10.13389/j.cnki.rao.2019.0217]
[15]张雨晴,邵毅,葛倩敏,等.玻璃体内注射雷珠单抗对年龄相关性黄斑变性患者眼表的影响[J].眼科新进展,2020,40(3):235.[doi:10.13389/j.cnki.rao.2020.0055]
　ZHANG Yuqing,SHAO Yi,GE Qianmin,et al.Clinical study of ocular surface damage caused by intravitreal injection of Ranibizumab in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2020,40(11):235.[doi:10.13389/j.cnki.rao.2020.0055]
[16]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130.[doi:10.13389/j.cnki.rao.2021.0027]
　HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(11):130.[doi:10.13389/j.cnki.rao.2021.0027]
[17]赵文,赵斐,李敏,等.CFH基因多态性与玻璃体液VEGF对年龄相关性黄斑变性患者抗VEGF疗效影响的交互作用[J].眼科新进展,2022,42(12):962.[doi:10.13389/j.cnki.rao.2022.0197]
　ZHAO Wen,ZHAO Fei,LI Min,et al.Interaction between complement factor H gene polymorphism and vascular endothelial growth factor in vitreous humor on anti-vascular endothelial growth factor efficacy in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(11):962.[doi:10.13389/j.cnki.rao.2022.0197]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-11-05